A Phase 1 interventional study of vorinostat and bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.
Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 1, and was the 4th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1
First in 2000; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 31 across the 17 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
20 studies in Multiple Myeloma by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 20 studies in Multiple Myeloma by Merck & Co., Inc, this one is the 16th largest by enrollment, is the only one that started in 2005, is one of 14 in phase 1, and was the 4th registered.
Merck & Co., Inc’s Multiple Myeloma studies by the year they started, since 2000.
1 of the studies testing vorinostat in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01297764Hackensack Meridian HealthA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing vorinostat in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 20 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purposes of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
Drug: vorinostat · Drug: bortezomib
Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Also known as: MK0683, Zolinza®, Suberoylanilide Hydroxamic Acid (SAHA)
Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
Also known as: Velcade
Mean Duration of Treatment With Vorinostat
Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity. Progressive disease was defined as: * \>25% increase in the level of serum monoclonal paraprotein. * 25% increase in 24-hour urinary light chain excretion. * \>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy. * Development of new bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia. Intolerable toxicity was based on the clinical judgment of the investigator.
Time frame: Day 1 to an event causing discontinuation from the study, assessed up to 29 months
Number of Participants With Dose Modifications of Either Vorinostat or Bortezomib Due to Adverse Experiences (AEs) After Treatment With Study Drug
An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
Time frame: Day 1 to disease progression, toxicity, or death, assessed up to 29 months
Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
Time frame: Day 1 to disease progression, toxicity, or death, assessed up to 29 months
Clinical AE Summary
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A serious AE (SAE) was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose.
Time frame: Day 1 up to disease progression, toxicity, or death, assessed up to 30 days after end of treatment (up to 30 months)
Laboratory AE Summary
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. A lab (S)AE was any lab value considered clinically significant in the investigator's judgment.
Time frame: Day 1 up to disease progression, toxicity, or death, assessed up to 29 months
| Milestone | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 10 | 6 | 6 | 6 |
| Completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 3 | 3 | 10 | 5 | 6 | 6 |
| Withdrew: Adverse event | 1 | 2 | 4 | 2 | 2 | 2 |
| Withdrew: Progressive disease | 2 | 1 | 5 | 3 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 |
Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity. Progressive disease was defined as: * \>25% increase in the level of serum monoclonal paraprotein. * 25% increase in 24-hour urinary light chain excretion. * \>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy. * Development of new bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia. Intolerable toxicity was based on the clinical judgment of the investigator.
| Days | All Participants |
|---|---|
| 200 mg | 4.6 (1 to 15) |
| 300 mg | 72.6 (28 to 210) |
| 400 mg | 107.1 (11 to 496) |
An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
| Participants | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| No dose modification | 3 | 3 | 8 | 4 | 3 | 3 |
| One dose modification | 0 | 0 | 2 | 2 | 1 | 0 |
| Two or more dose modifications | 0 | 0 | 0 | 0 | 2 | 3 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
| Days | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib | NA ± NA | NA ± NA | 58 ± 39 | 58 ± 11 | 128 ± 148 | 32 ± 5 |
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A serious AE (SAE) was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose.
| Participants | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| With one or more AEs | 3 | 3 | 10 | 6 | 6 | 6 |
| With no AEs | 0 | 0 | 0 | 0 | 0 | 0 |
| With drug-related AEs | 2 | 3 | 10 | 6 | 6 | 6 |
| With Serious AEs (SAEs) | 0 | 1 | 2 | 4 | 4 | 2 |
| With drug-related SAEs | 0 | 0 | 1 | 4 | 2 | 1 |
| Who died | 0 | 0 | 0 | 0 | 0 | 0 |
| Who discontinued due to AEs | 1 | 2 | 4 | 2 | 1 | 2 |
| Who discontinued due to drug-related AEs | 0 | 2 | 3 | 2 | 1 | 1 |
| Who discontinued due to SAEs | 0 | 0 | 1 | 2 | 0 | 1 |
| Who discontinued due to drug-related SAEs | 0 | 0 | 1 | 2 | 0 | 0 |
An AE was defined as any unfavorable/unintended change in the structure/function/chemistry of the body temporally associated with the use of study drug, or any worsening of a preexisting condition. A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a new cancer, or was an overdose. A lab (S)AE was any lab value considered clinically significant in the investigator's judgment.
| Participants | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| With one or more laboratory AEs | 1 | 1 | 3 | 0 | 2 | 3 |
| With no laboratory AEs | 2 | 2 | 7 | 6 | 4 | 3 |
| With drug-related laboratory AEs | 1 | 0 | 2 | 0 | 1 | 3 |
| With laboratory Serious AEs (SAEs) | 0 | 0 | 0 | 0 | 0 | 0 |
| With drug-related laboratory SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Who died | 0 | 0 | 0 | 0 | 0 | 0 |
| Who discontinued due to laboratory AEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Who discontinued due to drug-related lab AEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Who discontinued due to laboratory SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Who discontinued due to drug-related lab SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | — | 0/3 (0%) | 3/3 (100%) |
| Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | — | 1/3 (33.3%) | 3/3 (100%) |
| Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | — | 2/10 (20%) | 10/10 (100%) |
| Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | — | 4/6 (66.7%) | 6/6 (100%) |
| Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | — | 4/6 (66.7%) | 6/6 (100%) |
| Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 | — | 2/6 (33.3%) | 6/6 (100%) |
| Event | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/10 | 0/6 | 2/6 | 0/6 |
| PneumoniaInfections and infestations | 0/3 | 1/3 | 1/10 | 0/6 | 0/6 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/10 | 0/6 | 0/6 | 1/6 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 1/10 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/10 | 1/6 | 0/6 | 0/6 |
| Chest painGeneral disorders | 0/3 | 0/3 | 0/10 | 1/6 | 0/6 | 0/6 |
| DiverticulitisInfections and infestations | 0/3 | 0/3 | 0/10 | 1/6 | 0/6 | 0/6 |
| HypermagnesaemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 0/10 | 0/6 | 0/6 | 1/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/10 | 1/6 | 0/6 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/10 | 1/6 | 0/6 | 0/6 |
| Event | Vorinostat 200 mg + Bortezomib 0.7 mg/m^2 | Vorinostat 200 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 300 mg + Bortezomib 1.3 mg/m^2 | Vorinostat 400 mg + Bortezomib 0.9 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.1 mg/m^2 | Vorinostat 400 mg + Bortezomib 1.3 mg/m^2 |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 3/3 | 5/10 | 2/6 | 5/6 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 1/3 | 8/10 | 4/6 | 6/6 | 6/6 |
| NauseaGastrointestinal disorders | 2/3 | 3/3 | 6/10 | 5/6 | 3/6 | 6/6 |
| FatigueGeneral disorders | 2/3 | 3/3 | 5/10 | 6/6 | 2/6 | 5/6 |
| VomitingGastrointestinal disorders | 1/3 | 2/3 | 6/10 | 3/6 | 3/6 | 5/6 |
| Abdominal distensionGastrointestinal disorders | 2/3 | 1/3 | 0/10 | 0/6 | 0/6 | 0/6 |
| ConstipationGastrointestinal disorders | 0/3 | 0/3 | 0/10 | 2/6 | 4/6 | 3/6 |
| Weight decreasedInvestigations | 1/3 | 2/3 | 0/10 | 0/6 | 1/6 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 1/3 | 1/10 | 0/6 | 2/6 | 4/6 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 2/3 | 1/10 | 1/6 | 0/6 | 0/6 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 60.6 ± 8.1 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 13 |
| Male | 21 |
No study locations are listed for this record.
The record gives a start of Sep 2005, a primary completion of Dec 2009 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat